Tilomisole
Tilomisole (Wy 18251) is a benzimidazothiazole experimental agent with anti-inflammatory activity. Tilomisole causes less agranulocytosis than levamisole, but retains immunomodulating capabilities. Tilomisole is orally active. Tilomisole has the potential for the research of cancer and inflammation[1][2].
Product Specifications
CAS Number
58433-11-7
Product Name Alternative
Wy 18251
UNSPSC
12352005
Target
COX
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tilomisole.html
Solubility
10 mM in DMSO
Smiles
O=C(CC1=C(C2=CC=C(Cl)C=C2)N3C4=C(C=CC=C4)N=C3S1)O
Molecular Formula
C17H11ClN2O2S
Molecular Weight
342.80
References & Citations
[1]Dillman RO, et al. WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients. Mol Biother. 1992;4 (1) :10-14.|[2]Darwish SA, et al. New tilomisole-based benzimidazothiazole derivatives as anti-inflammatory agents: Synthesis, in vivo, in vitro evaluation, and in silico studies [published online ahead of print, 2022 Jan 29]. Bioorg Chem. 2022;120:105644.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AMG52001 100 μg
Recombinant Mouse MSLN/Mesothelin Protein, C-His (Active)
Sign In for Pricing
View Details 